Stellant Secu. (526071)

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 726.67% reflects a rapidly expanding, albeit very small, revenue base.
• Reported ROCE of 106.67% suggests high return on capital employed, if the underlying earnings quality holds.
• Headline P/E of 7.44 is optically cheap.
• Piotroski F-Score of 4/9 is weak but not zero; some financial health signals exist.

Concerns

• Latest quarter has ₹1 Cr sales against ₹-5 Cr net profit; losses are more than 15x the implied book value of ~₹0.32 Cr.
• Profit growth is -4,740%, and dividend yield is 0%; no shareholder return.
• Current price ₹27.09 is far below the 52-week range of ₹98.93–₹683.80, indicating either collapse or data unreliability.
• Promoter holding is N/A and FairStock score is insufficient data – lack of transparency.

AI Analysis

As a value investor, I don’t buy a stock just because it looks statistically cheap; I buy a business. Stellant Secu, a tiny other financial services company with a ₹2 Cr market cap, fails that test. At ₹27.09, the stock trades at 6.29 times book value of ₹4.31, while the latest quarter shows sales of just ₹1 Cr and a net loss of ₹5 Cr. Doing the arithmetic: market cap of ₹2 Cr divided by P/B of 6.29 implies total book value of about ₹0.32 Cr. That means one quarter’s loss is more than fifteen times the entire net worth. Mr. Graham would call this speculative destruction, not investment. The P/E of 7.44 and PEG of 0.01 are meaningless when profit growth is -4,740% and the Piotroski F-score is only 4/9. A 726.67% sales growth rate sounds exciting, but from such a small base and with losses widening, it is not evidence of a franchise. The 106.67% ROCE might attract attention, but it is not durable when the income statement is bleeding cash. The 52-week range of ₹98.93 to ₹683.80 against today’s price of ₹27.09 is either a catastrophic collapse or a data inconsistency; in either case, it destroys confidence. There is no dividend, promoter holding is not disclosed, and the FairStock score is insufficient data. I see no moat, no pricing power, and no margin of safety. This is not a wonderful company at a fair price; it’s a questionable business at a price that still demands too much for the risk. I would keep my capital elsewhere.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer